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1382particular, we see huge possibilities for future thera-
peutic interventions and thus improvement of car-
diovascular function and, thereby, quality of life in
patients with cancer. With regard to spiroergometry
assessment, a cutoff value for the RER value was
indeed $1.10 in a number of studies, as this sup-
posedly indicates maximal effort and prognostic
sensitivity. This is, however, not the only cutoff used
in previous studies. Although some authors have
used a cutoff >1.05 or >1.00 (2), others have sug-
gested that a cutoff >1.00 or >0.95 could be accept-
able if this represents a change of at least 0.15 over
baseline (3,4). Using data from more than 1,700 pa-
tients with heart failure with reduced ejection frac-
tion, Chase et al. (5) recently reported that both peak
VO2 and VE/VCO2 slope remained signiﬁcant predictors
of major adverse cardiac events in all subgroups of
RER, even in those with an RER <1.00. We, therefore,
strongly believe in the methodology that we applied
in this prospective study of cardiovascular function
and exercise capacity in patients with colorectal
cancer.
Additional analyses are always welcome, but due
to the overwhelming amount of data that our study
produced, we had to limit ourselves to those param-
eters that we considered most important.Larissa Cramer
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427–32.The Importance of the
Cardiac Cycle in the
Imaging Criteria for
Left Ventricular
NoncompactionWe read with great interest the recent review by
Arbustini et al. (1) highlighting the different aspects
of the left ventricular noncompaction (LVNC). In this
paper, the authors review pathophysiology, anatomy,
epidemiology, genetics, and the imaging for diagnosis
and other aspects related to this interesting and not
well known entity. However, 1 limitation of the re-
view, especially regarding the imaging diagnosis with
cardiac magnetic resonance, should be also brought
to the readers’ attention.
The authors stated that for an echocardiography
diagnosis after careful evaluation of all criteria, the
most important echocardiographic criterion remains a
noncompacted/compacted ratio greater than 2.0 in
end-systole, well known as the Jenni criteria (2). One
important detail in this case is that the measurement
must be performed during the end-systolic phase of
the cardiac cycle.
The authors do not provide by the other side a
completely clear criteria for the measurement on CMR
that they consider the technique that conﬁrms diag-
nosis in the central illustration. They mentioned
a noncompacted/compacted ratio greater than 2.3
on CMR be considered the cutoff for an LVNC diag-
nosis (3), the Petersen criteria, but they neglected to
mention when we must perform this measurement,
something of importance due to the different moment
in the cardiac cycle at which it must be performed
compared with echocardiography. The diagnosis with
CMR is suggested when the noncompacted/com-
pacted ratio is greater than 2.3 during end-diastole.
In our opinion, there is a lot of room for improve-
ment in the diagnosis of this entity due to the im-
portant differences that an incorrect measurement
could cause and also whether we need to take into
account a different moment in the cardiac cycle at
which to perform the measurements, depending on
what imaging technique we use for the diagnosis or
even where we must make the measurement (4).
Maybe it is time to add genetics to improve this
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1383imaging-based suspect diagnosis, as highlighted in the
editorial by Garcia-Pavia and de la Pompa (5) with a
review of all the imaging criteria available to the date.*Rafael Vidal-Perez, MD, PhD
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1981–3.REPLY: The Importance of Cardiac Cycle
in the Imaging Criteria for Left Ventricular
NoncompactionWe appreciate the letter by Dr. Vidal-Perez and col-
leagues as it highlights the current lack of consensus
on nosology and diagnostic criteria of left ventricu-
lar noncompaction (LVNC). In daily clinical practice,
the presence of noncompaction in the absence of
dilated cardiomyopathy (DCM) or left ventricular
hypertrophy (LVH) is often annotated as a des-
criptive ﬁnding but not systematically labeled as
cardiomyopathy, especially when identiﬁed as an
incidental ﬁnding in otherwise functionally normal
hearts. In clinical reports, the term hypertra-
beculation or increased trabeculation followed by
topographic indications is far more common than the
diagnosis of LVNC. The question remains as to when
should LVNC also be diagnosed as LVNC cardiomy-
opathy (1)?Imaging provides quantiﬁcation on the anatomy of
the layers of the left ventricle as well as the possibility
of measuring ratios between compacted and non-
compacted layers. The thickness of the left ventricu-
lar layers are taken in end-diastole with cardiac
magnetic resonance (2). However, thickness of the
left ventricular layers can be measured with echo-
cardiography in both end-systole and end-diastole, as
indicated by Jenni et al. (3) and Paterick et al. (4).
Paterick et al. (4) selected to measure in end-diastole
because the thickness of compacted and non-
compacted layers was deemed more precise in end-
diastole. Chamber wall thickness measurements
performed with echocardiography in end-diastole is
currently consistent with the convention of the
American Society of Echocardiography. The absence
of consensus criteria is partly explained by the still
limited knowledge on the natural history of the dis-
ease, namely, the evolution of LVNC with normal left
ventricular size and function at onset and later
developed left ventricular dilation and eventually
dysfunction or LVH.
The point raised by Vidal-Perez and colleagues
about genetics is appropriate more as a question
rather than an answer as genes only causing LVNC
and not associated with DCM or hypertrophic car-
diomyopathy have not been identiﬁed. Although we
strongly support genetic testing in all cardiomyopa-
thies, a key problem remains the deﬁnition of LVNC
and consequently its diagnosis and distinction with
features of prominent, increased trabeculation. The
measurement of the thickness of the epicardial com-
pacted layer could add information to the ratio of
compaction/noncompaction. For example, a thick
epicardial layer could guarantee a normal function
whatever the noncompaction is.
A major clinical problem speciﬁcally associated
with LVNC is the risk of mural endocardial thrombotic
stratiﬁcation and thromboembolic complications. The
presence of deep recesses may favor the formation of
mural thrombi, but this only occurs in dysfunctional
hearts. No case to date with LVNC and normal cardiac
function has been associated with mural thrombosis
or embolic complications. These latter cases occur
typically in dilated and dysfunctional hearts with
LVNC, which is DCM with LVNC. The open question
is when to start anticoagulant treatment in these
patients.Eloisa Arbustini, MD
Frank Weidemann, MD
*Jennifer L. Hall, PhD
*Lillehei Heart Institute and Division of Cardiology
Department of Medicine
